SYBX Stock Forecast 2025-2026
Distance to SYBX Price Targets
SYBX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Synlogic (SYBX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SYBX and similar high-potential opportunities.
Latest SYBX Stock Price Targets & Analyst Predictions
SYBX has shown a year-to-date change of -5.7% and a 1-year change of -25.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for SYBX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYBX Analyst Ratings
SYBX Price Target Range
Latest SYBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Upgrade | $0.00 |
| Feb 9, 2024 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $1.00 |
| Feb 9, 2024 | HC Wainwright & Co. | Ed Arce | Sell | Downgrade | $0.00 |
| Feb 9, 2024 | Chardan Capital | Keay Nakae | Neutral | Downgrade | $0.00 |
| Dec 11, 2023 | Alliance Global Partners | James Molloy | Buy | Initiates | $30.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Aug 11, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $6.00 |
| Jul 11, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Jun 6, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Jun 6, 2023 | Chardan Capital | Keay Nakae | Buy | Maintains | $6.00 |
| May 19, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| May 15, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Apr 27, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Assumes | $5.00 |
| Mar 30, 2023 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.50 |
| Nov 11, 2022 | Chardan Capital | Keay Nakae | Buy | Maintains | $7.00 |
| Oct 18, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $8.00 |
| May 13, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $6.00 |
| Mar 18, 2022 | SVB Leerink | Joseph Schwartz | Outperform | Maintains | $8.00 |
| Nov 24, 2021 | Oppenheimer | Outperform | Upgrade | $0.00 | |
| Nov 11, 2021 | SVB Leerink | Joseph Schwartz | Outperform | Maintains | $11.00 |
Synlogic Inc. (SYBX) Competitors
The following stocks are similar to Synlogic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Synlogic Inc. (SYBX) Financial Data
Synlogic Inc. has a market capitalization of $15.44M with a P/E ratio of -0.7x. The company generates $8,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -197,212.5% and return on equity of -102.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Synlogic Inc. (SYBX) Business Model
About Synlogic Inc.
Develops synthetic biotic medicines for unmet medical needs.
Synlogic Inc. operates as a clinical-stage biotechnology company focused on creating innovative therapeutics through synthetic biology. The company engineers beneficial probiotic bacteria to perform specific metabolic functions, generating revenue through collaborations with academic institutions and industry partners while advancing its research and development.
Synlogic's unique approach targets complex diseases that traditional pharmaceuticals struggle to address, including genetic and metabolic disorders, immunological conditions, and oncology. The company aims to revolutionize patient care by expanding treatment options in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Country
United States
IPO Year
2015
Website
www.synlogictx.comSynlogic Inc. (SYBX) Latest News & Analysis
Synlogic, Inc. (Nasdaq: SYBX) reported its Q3 2024 financial results and offered a corporate update on its progress in developing novel therapeutics for serious diseases.
Synlogic's financial results and corporate update signal its progress and potential in the biopharmaceutical sector, which could impact stock performance and investor sentiment.
Synlogic, Inc. (Nasdaq: SYBX) reported its Q2 2024 financial results and provided a corporate update on August 8, 2024, focusing on advancements in novel therapeutics for serious diseases.
Synlogic's Q2 2024 financial results and corporate update signal its financial health and strategic direction, impacting stock performance and investor sentiment in the biopharmaceutical sector.
The adage "Sell in May and go away" suggests that stocks historically underperform from May to October, leading some investors to remain inactive during this period.
The adage suggests a seasonal trend where stocks may lag from May to October, prompting investors to adjust their strategies to mitigate potential losses during this period.
Synlogic Reports First Quarter 2024 Financial Results
10 months agoSynlogic, Inc. (Nasdaq: SYBX) reported its Q1 2024 financial results and provided a corporate update on May 14, 2024.
Synlogic's Q1 2024 financial results and corporate update may influence stock performance and investor sentiment, reflecting the company's progress and potential in biopharmaceuticals.
Synlogic, Inc. (Nasdaq: SYBX) reported its financial results for Q4 and the full year ending December 31, 2023, focusing on advancements in therapeutics for serious diseases.
Synlogic's financial results may indicate its performance and growth potential, impacting stock valuation and investor sentiment in the biopharmaceutical sector.
Synlogic, Inc. (SYBX) reported a quarterly loss of $1.71 per share, worse than the expected loss of $1.11, but an improvement from a loss of $3.60 per share a year earlier.
Synlogic's larger-than-expected quarterly loss may signal ongoing financial challenges, impacting investor confidence and stock performance, despite an improvement from last year.
Frequently Asked Questions About SYBX Stock
What is Synlogic Inc.'s (SYBX) stock forecast for 2025?
Analyst forecasts for Synlogic Inc. (SYBX) are not currently available. The stock is trading at $1.32.
Is SYBX stock a good investment in 2025?
According to current analyst ratings, SYBX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYBX stock?
Price predictions from Wall Street analysts for SYBX are not currently available. The stock is trading at $1.32.
What is Synlogic Inc.'s business model?
Synlogic Inc. operates as a clinical-stage biotechnology company focused on creating innovative therapeutics through synthetic biology. The company engineers beneficial probiotic bacteria to perform specific metabolic functions, generating revenue through collaborations with academic institutions and industry partners while advancing its research and development.
What is the highest forecasted price for SYBX Synlogic Inc.?
Price targets from Wall Street analysts for SYBX are not currently available. The stock is trading at $1.32.
What is the lowest forecasted price for SYBX Synlogic Inc.?
Price targets from Wall Street analysts for SYBX are not currently available. The stock is trading at $1.32.
What is the overall SYBX consensus from analysts for Synlogic Inc.?
The overall analyst consensus for SYBX is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are SYBX stock price projections?
Stock price projections, including those for Synlogic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
